Serina Therapeutics, Inc.
SER
Last
$1.97
Day
-2.0%
1y
-64.0%
5y
-86.5%
52w
-64.8%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1232d
EMA 21
2.14
EMA 50
2.23
EMA 200
2.55
20d high
-21.2%
5y high
-89.9%
5y range
4th
Positions held
Your positionsSER isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$2.24
Stop
$1.82
Stop distance
7.6%
Target vs last
+13.7%
Fundamentals
| Market cap | $51.05M | Enterprise value | $31.78M | Trailing P/E | — | Forward P/E | -1.91 |
| PEG | — | Price / book | 2.73 | Beta | 0.16 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.1% | ROA | -92.3% | Debt / equity | 0.20 |
| Current ratio | 6.65 | Free cash flow | -$12.35M | Analyst recommendation | none | Mean target | $9.50 |
| 52w high | $5.71 | 52w low | $1.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$6.4M | -$6.9M | -$3.3M | -$4.6M | -$6.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.8M | -$6.3M | -$6.2M | -$6.4M | -$5.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $3.0M | $0.5M | — |
| Op margin | — | — | -104.3% | -454.1% | — |
| Net income | -$19.2M | -$11.1M | $5.3M | -$2.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$24.0M | -$17.0M | -$3.1M | -$2.3M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-10 · Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-13 · Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-24 · Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
2026-07-23 · Serina Completes Enrollment, Dosing in First Cohort of Phase 1b Trial in Parkinson's Disease
2026-07-22 · Serina Therapeutics Appoints Farrell Simon to its Board of Directors
Price (daily)
Full chart · RSI · MACD · patternsSER · daily-13.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin